866-997-4948(US-Canada Toll Free)

Prosthetic joint infections - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 39 Pages

Prosthetic joint infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic joint infections Pipeline Review, H2 2016, provides an overview of the Prosthetic joint infections (Musculoskeletal Disorders) pipeline landscape.

Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease.Treatment includes antimicrobial therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prosthetic joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 2, 2 and 1 respectively.

Prosthetic joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic joint infections (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Prosthetic joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prosthetic joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prosthetic joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic joint infections (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prosthetic joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Prosthetic joint infections Overview 6
Therapeutics Development 7
Pipeline Products for Prosthetic joint infections - Overview 7
Prosthetic joint infections - Therapeutics under Development by Companies 8
Prosthetic joint infections - Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Unknown Stage Products 11
Prosthetic joint infections - Products under Development by Companies 12
Prosthetic joint infections - Companies Involved in Therapeutics Development 13
Cempra Inc 13
Motif Bio Plc 14
Nabriva Therapeutics AG 15
Telephus Medical LLC 16
Prosthetic joint infections - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
EPP-001 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
fusidic acid - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
lefamulin acetate - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
MTF-101 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
TNP-2092 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
TPH-101 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Prosthetic joint infections - Dormant Projects 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables
Number of Products under Development for Prosthetic joint infections, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Comparative Analysis by Unknown Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Prosthetic joint infections - Pipeline by Cempra Inc, H2 2016 13
Prosthetic joint infections - Pipeline by Motif Bio Plc, H2 2016 14
Prosthetic joint infections - Pipeline by Nabriva Therapeutics AG, H2 2016 15
Prosthetic joint infections - Pipeline by Telephus Medical LLC, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Prosthetic joint infections - Dormant Projects, H2 2016 37

List of Figures
Number of Products under Development for Prosthetic joint infections, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *